GlassScriptPhysician profile
Thomas C Pitts
NPI 1750624656
$211,240.63
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103K · 2020: $60K · 2021: $17K · 2022: $29K · 2023: $2,303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,275 · Food and Beverage: $28.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,275.00 |
| Food and Beverage | $28.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $200,216.36 | 2019-2023 | Ultomiris |
| Catalyst Pharmaceuticals, INC. | $7,314.98 | 2020-2022 | |
| Amgen INC. | $663.21 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $386.59 | 2020-2021 | |
| Horizon Therapeutics Plc | $351.09 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $305.26 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $273.64 | 2019-2022 | |
| Abbvie INC. | $243.07 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $239.63 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $227.07 | 2022 | |
| Medtronic, INC. | $173.65 | 2022 | |
| Nevro Corp. | $131.19 | 2019-2022 | |
| Allergan, INC. | $99.02 | 2020 | |
| Mdd US Operations, LLC | $83.48 | 2021 | |
| Redhill Biopharma INC. | $62.19 | 2020-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $58.39 | 2020-2022 | |
| Biogen, INC. | $57.40 | 2020-2021 | |
| Collegium Pharmaceutical, INC. | $53.37 | 2020-2021 | |
| Scilex Pharmaceuticals INC. | $43.22 | 2021 | |
| Almatica Pharma LLC | $38.73 | 2021 | |
| Amneal Pharmaceuticals LLC | $35.64 | 2022 | |
| Depuy Synthes Sales INC. | $35.55 | 2019-2021 | |
| Akcea Therapeutics, INC. | $27.96 | 2019 | |
| Boston Scientific Corporation | $21.81 | 2021 | |
| Bioventus LLC | $19.48 | 2020 | |
| Pfizer INC. | $18.62 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $16.85 | 2022 | |
| Pacira Therapeutics, INC. | $15.81 | 2019 | |
| Forte Bio-Pharma LLC | $15.65 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $11.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Pitts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.